• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study finds dangerous increases in patients mixing opioids, benzodiazepines or Z-drugs

Bioengineer by Bioengineer
January 17, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The number of Americans taking a dangerous combination of opioids along with drugs commonly prescribed for pain, insomnia and anxiety ‘is alarming,’ says study’s author

The number of Americans taking a dangerous combination of both opioids and benzodiazepines — a group of drugs commonly prescribed for pain, insomnia and anxiety — increased by 250 percent over a 15-year period, while there was an 850 per cent increase in patients taking both benzodiazepines and so-called Z-drugs, which act similarly to benzodiazepines, according to a new study published in the journal Sleep.

The research by Dr. Nicholas Vozoris, an associate scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto, relies on data from eight National Health and Nutrition Examination Survey (NHANES) cycles between 1999 and 2014. It found the prevalence of benzodiazepine and opioid co-usage in the United States in 2014 was 1.36 percent, while the prevalence of benzodiazepine and Z-drug co-usage was 0.47 percent.

Dr. Vozoris found the increases in co-usage very concerning given that these drug-use patterns are associated with increased risks for serious adverse outcomes including breathing problems and death.

“While the proportions may seem small, these percentages at a population-level correspond to millions of people and the growth of these numbers is alarming,” said Dr. Vozoris, a sleep medicine doctor who often sees patients in his clinic who are taking a worrisome or dangerous combination of drugs.

“The FDA has gone as far as to issue its strongest form of safety warning about this suboptimal prescribing practice and mixing of opioids and benzodiazepines.”

The 1.36 percent prevalence of benzodiazepine and opioid co-usage translated to about 4.3 million people, while the 0.47 percent prevalence of benzodiazepine and Z-drug co-usage amounted to about 1.5 million people.

Dr. Vozoris said he’s seen a lot of confusion about benzodiazepines and Z-drugs among both patients and other medical professionals.

Commonly prescribed benzodiazepines include alprazolam, clonazepam and lorazepam while Z-drugs include zaleplon, zolpidem and zopiclone.

“There are doctors and members of the public often not realizing that Z-drugs are very similar in action to benzodiazepine drugs — sometimes patients get put on both a benzo and a Z-drug and think they’re two very different drugs,” Dr. Vozoris said.

“I wanted to understand the trends in use of such worrisome drug combinations and which types of individuals were more likely to receive such drug combinations.”

###

Media Contact
Michael Oliveira
[email protected]
416-864-5047

Tags: AddictionCritical Care/Emergency MedicineDrugsMedicine/HealthPainPharmaceutical SciencePharmaceutical SciencesPublic Health
Share12Tweet7Share2ShareShareShare1

Related Posts

Monoclonal Antibodies Shield Against Drug-Resistant Klebsiella

October 1, 2025
blank

Oncotarget Editor-in-Chief Wafik S. El-Deiry to Chair 2025 WIN Symposium in Partnership with APM in Philadelphia

October 1, 2025

Linking Nurses’ Emotional Skills to Care Competence

October 1, 2025

Tracking Ovarian Cancer Evolution via Cell-Free DNA

October 1, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    90 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    65 shares
    Share 26 Tweet 16
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Monoclonal Antibodies Shield Against Drug-Resistant Klebsiella

High-Frame Ultrasound Reveals Liver Cancer Insights

Impact of Reaction Time on α-MnO₂ in Zinc-Ion Batteries

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.